Coming off the back of the company-defining results reported last week in the glaucoma pig model,
these results also exceeded our expectations and profoundly demonstrate the efficacy of EmtinB in MS
and across a number of other neurodegenerative conditions”, commented Matthew Liddelow, CEO and
Managing Director of NeuroScientific Biopharmaceuticals. “These results also indicate positive
implications for EmtinB treatment of demyelinating conditions that affect the optic nerve, such as optic
neuritis and the company plans to further explore this as part of our ophthalmology R&D program.”
- Forums
- ASX - By Stock
- Ann: Positive Results in MS Study
Coming off the back of the company-defining results reported...
- There are more pages in this discussion • 77 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.7¢ |
Change
-0.001(2.08%) |
Mkt cap ! $6.796M |
Open | High | Low | Value | Volume |
4.8¢ | 4.8¢ | 4.7¢ | $2.173K | 45.80K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 4.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.9¢ | 45000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.045 |
1 | 100000 | 0.044 |
3 | 276511 | 0.043 |
1 | 15000 | 0.042 |
1 | 100000 | 0.041 |
Price($) | Vol. | No. |
---|---|---|
0.049 | 45000 | 1 |
0.051 | 200000 | 1 |
0.052 | 161625 | 3 |
0.054 | 224000 | 1 |
0.055 | 237701 | 3 |
Last trade - 15.56pm 29/03/2024 (20 minute delay) ? |
|
|||||
Last
4.8¢ |
  |
Change
-0.001 ( 2.13 %) |
|||
Open | High | Low | Volume | ||
4.8¢ | 4.8¢ | 4.8¢ | 20988 | ||
Last updated 15.28pm 29/03/2024 ? |
Featured News
NSB (ASX) Chart |